The purpose of the Journey Study is to evaluate the effectiveness, safety, and tolerability of a study drug
in participants with schizophrenia who did not respond well enough to antipsychotic therapy and to find out how well the study drug works as an add-on therapy.
This study is evaluating the effectiveness of the study drug, valbenazine, compared to a placebo on symptoms of schizophrenia including hallucinations and confused thoughts. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients.
You may Qualify if:
**There are additional eligibility requirements,
which the study doctor can explain to you**
The total length of participation in the Journey Study is
up to 16 weeks, which includes 7 on-site study visits. This study comprises the following periods:
Copyright © 2023 Health Synergy Clinical Research - All Rights Reserved.
Powered by GoDaddy Website Builder